Volume 6.22 | Jun 19

Prostate Cell News 6.22 June 19, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
New Discovery Could Explain How Prostate Cancer Becomes Lethal
Researchers identified two new key players in the development of prostate cancer, which is the second most common malignancy in men and can become highly aggressive. The two players, PCA3 and PRUNE2, unusually come from the same location in the genome. They also physically interact and regulate each other’s activity. [Press release from the University of New Mexico discussing online prepublication in Proceedings of the National Academy of Sciences] Press Release | Abstract | Full Article
Going to ISSCR 2015? We’ll see you there!
PUBLICATIONS (Ranked by impact factor of the journal)

A MicroRNA Code for Prostate Cancer Metastasis
Investigators showed that loss of miR-15 and miR-16 in cooperation with increased miR-21 expression promote prostate cancer spreading and bone lesions. This combination of microRNAs endows bone-metastatic potential to prostate cancer cells. [Oncogene] Full Article

CRISPR/Cas9-Mediated Gene Knockout of NANOG and NANOGP8 Decreases the Malignant Potential of Prostate Cancer Cells
Investigators established NANOG and NANOGP8-knockout DU145 prostate cancer cell lines using the CRISPR/Cas9 system. Knockouts of NANOG and NANOGP8 significantly attenuated malignant potential, including sphere formation, anchorage-independent growth, migration capability, and drug resistance, compared to parental DU145 cells. [Oncotarget] Full Article

Hypoxia Induces Triglycerides Accumulation in Prostate Cancer Cells and Extracellular Vesicles Supporting Growth and Invasiveness following Reoxygenation
Researchers report that under hypoxia, human prostate cancer cells, and extracellular vesicles released by these cells, are significantly enriched in triglycerides due to the activation of lipogenesis-related enzymes and signaling molecules. [Oncotarget] Full Article

GLIPR1-ΔTM Synergizes with Docetaxel in Cell Death and Suppresses Resistance to Docetaxel in Prostate Cancer Cells
Scientists evaluated the hypothesis that the combination treatment with docetaxel and GLIPR1-ΔTM will synergistically induce greater cell death and inhibit the emergence of resistance and development of metastatic potential in prostate cancer cells. [Mol Cancer] Abstract | Full Article

Development of Novel Radio-Chemotherapy Approaches Targeting Prostate Tumor Progenitor Cells Using Nanohybrids
Researchers describe the synthesis of biocompatible, catechin-loaded and gelatin-conjugated carbon nanotubes with anticancer properties and demonstrated their potential for the eradication of prostate cancer stem cells in combination with X-ray irradiation. [Int J Cancer] Abstract

Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts
Scientists investigated the ability of Pim kinases to promote metastatic growth of prostate cancer cells in two xenograft models for human prostate cancer. They also evaluated the efficacy of Pim-selective inhibitors to antagonize these effects. [PLoS One] Full Article

Oncolytic Virus Carrying shRNA Targeting SATB1 Inhibits Prostate Cancer Growth and Metastasis
The authors constructed ZD55-SATB1, an oncolytic adenovirus ZD55 carrying shRNA targeting SATB1, and investigated its effects on the inhibition of prostate cancer growth and metastasis. ZD55-SATB1 was constructed and used to infect human prostate cancer cell lines DU145 and LNCaP. [Tumor Biol] Abstract

Metformin Induces ER Stress-Dependent Apoptosis through miR-708-5p/NNAT Pathway in Prostate Cancer
Scientists identified miR-708-5p as a novel target of metformin in prostate cancer cells. Metformin promotes increased expression of miR-708-5p, leading to suppression of endoplasmic reticulum (ER) membrane protein neuronatin expression and subsequently induces apoptosis of prostate cancer cells through the ER stress pathway. [Oncogenesis] Full Article


A Randomized Non-Comparative Phase II Trial of Cixutumumab (IMC-A12) or Ramucirumab (IMC-1121B) plus Mitoxantrone and Prednisone in Men with Metastatic Docetaxel-Pretreated Castration-Resistant Prostate Cancer
A non-comparative randomized Phase II study evaluated cixutumumab or ramucirumab plus mitoxantrone and prednisone in metastatic castration-resistant prostate cancer. [Eur J Cancer] Abstract

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Scientists investigated whether AR-V7–positive patients would retain sensitivity to taxane chemotherapy and whether AR-V7 status would have a differential impact on taxane-treated men compared with enzalutamide- or abiraterone-treated men. [JAMA Oncol] Full Article | Press Release

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
Using Circulating Tumor Cells to Inform on Prostate Cancer Biology and Clinical Utility
The authors review technologies used to detect and characterize circulating tumor cells (CTCs), and the potential biological and clinical utility of CTC molecular profiling in men with metastatic prostate cancer. [Crit Rev Clin Lab Sci] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
RestorGenex Corporation announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, “RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model” will be presented. [Press release from RestorGenex Corporation discussing to be research presented at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), Rome] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
Lilly and Dana-Farber Cancer Institute Announce Research Collaboration
Eli Lilly and Company and Dana-Farber Cancer Institute announced a multi-year collaboration to research new medicines under development to fight cancer. Over the course of three years, Dana-Farber will provide research and development expertise for a number of early-stage Lilly oncology compounds. [Eli Lilly and Company] Press Release

Anonymous Donor Gives $20 Million for Cancer Research at Wake Forest Baptist
Wake Forest Baptist Medical Center has received $20 million to study the effects of muscadine grape extract on prostate and breast cancers. The gift by a donor who wishes to remain anonymous is the largest ever received by the Medical Center. [Wake Forest Baptist Medical Center] Press Release

Ludwig Cancer Research Expands Presence in Lausanne
Ludwig Cancer Research announced that it is opening a new branch in Lausanne, Switzerland. The branch will be focused primarily on applied cancer immunology and the design of novel molecular and cell-based immunotherapies. [Ludwig Cancer Research] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cancer Diagnosis & Therapy Congress
September 3-4, 2015
London, United Kingdom

NEW Frontiers in Stem Cells and Regeneration
September 27-October 3, 2015
Woods Hole, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellow- Oncology (Oregon Health & Science University)

Research Technician (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellows – Molecular Mechanisms of Prostate Cancer Progression and Therapeutic Resistance (Tulane University School of Medicine)

Postdoctoral Fellowship – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic Lerner Research Institute)

Research Scientists – Tissue Biorepository and Data Resource for Prostate Cancer (NYU Langone Medical Center)

Research Assistant Professor or Instructor – Prostate Cancer (Thomas Jefferson University)

Postdoctoral Positions – Cancer, Stem Cell, and Developmental Biology (Columbia University Medical Center)

Senior Postdoctoral Position – Prostate Cancer (Institut Paoli Calmettes)

Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us